Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-06-18
1993-10-19
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142372, 514307, 514314, 514385, 514396, 514397, 514381, 514382, 544139, 546144, 546167, 548113, 548114, 548115, 548252, 548254, 5482662, 5483111, 5483114, 5483121, 5483255, 5483345, 5483355, 5483381, 5483401, 5483415, 5483421, 5483425, 5483435, 5483461, C07D40310, C07D40514, C07D40914, A61K 31415
Patent
active
052545466
ABSTRACT:
Substituted imidazoles such as ##STR1## which are useful as angiotensin II receptor inhibitors. These compounds have activity in treating hypertension and congestive heart failure.
REFERENCES:
patent: 3772315 (1973-11-01), Regel et al.
patent: 4207324 (1980-06-01), Matsumura et al.
patent: 4226878 (1980-10-01), Iizuka et al.
patent: 4328349 (1982-05-01), Grayboyes et al.
patent: 4340598 (1982-07-01), Furukawa et al.
patent: 4347364 (1982-08-01), Walser et al.
patent: 4347365 (1982-08-01), Walser et al.
patent: 4355040 (1982-10-01), Furukawa et al.
patent: 4379927 (1983-04-01), Vorbruggen
patent: 4448781 (1984-05-01), Cross
patent: 4463011 (1984-07-01), Ogata et al.
patent: 4532231 (1985-07-01), Frazee
patent: 4689182 (1987-08-01), Rafferty et al.
patent: 4755518 (1988-07-01), Rafferty et al.
Burger, A. Medicinal Chemistry, Second Edition, New York, pp. 565-571, 578-581, 600-601 (1960).
Denkewalter et al., Progress in Drug Research, vol. 10, pp. 510-512 (1966).
Wong et al., Abstract No. 30, Hypertension, p. 340, vol. 12, No. 3, Sep. 1988 for High Blood Pressure Council Mtg., San Francisco, Calif., Sep. 28-Oct. 1, 1988 "X-6803 Methyl 2-N-Butyl-1-(4-(2-Carboxybenzamido)Benzyl)-4-Chloroimidazole-5-Acetate, Sodium Salt): A Novel Nonpeptide Angiotensin II Receptor Antagonist".
Chiu et al., Abstract No. 118.11, The Pharmacologist, vol. 30, p. A165, 1988, for ASPET meeting, Montreal, Canada, Oct. 9-13, 1988: "Nonpeptide Angiotensin II (AII) Receptor Antagonists: Structure Function Studies".
Wong et al., "Nonpeptide Angiotensin II Receptor Antagonists. I. Pharmacologic Characterization of 2-n-Butyl-4-Chloro-1(2-Ch-orobenzyl)imidazole-5-Acetic Acid, Sodium Salt (S-8307)," J. Pharmacology and Experimental Therapeutics vol. 247, No. 1, pp. 1-7 (1988).
Chiu et al., "Non-peptide angiotensin II Receptor Antagonists. II. Pharmacology of S-8308," European Journal of Pharmacology, vol. 157, pp. 13-21 (1988).
Dzau et al., N. Eng. J. Med. 310:347, 1984.
Lindgren et al., Eur. J. Pharmacol. 135:383, 1987.
Zatz et al., Kidney International, vol. 31, Suppl. 20, pp. S123-S129 (1987).
Wong et al., Life Sciences, vol. 27, pp. 1291-1297 (1980).
Schmidt et al., J. Cardiovascular Pharmacology, vol. 8, pp. S100-S5105 (1986).
Torii H., Takeda Kenkyushoho, 41, No. 3/4, 180-191, (1982).
Pals et al., Circ. Research, vol. 29, pp. 673-681 (1971).
Streeten et al., Handbook of Hypertension, vol. 5, pp. 246-271 (1984).
Keeton T. K. et al., Pharmacol. Rev., vol. 31, No. 2, pp. 81-227, (1981).
Weinberger M. H. et al., Medical Clincs N. America, vol. 71, No. 5, (1987), pp. 979-991.
Dunn, M. J., Hospital Practice, vol. 19, pp. 99-113, (1984).
Satoh et al., Cir. Res., 36/37 (Suppl. I):I-89 to I-96, (1975).
Blasingham et al., Am. J. Physiol., vol. 239, F 360-F365, (1980).
Wong et al., J. Pharmacol. Exp. Therm. vol. 215, pp. 104-109, (1980).
Ardecky Robert J.
Carini David J.
Duncia John Jonas V.
Wong Pancras C.
E. I. Du Pont de Nemours and Company
Higel Floyd D.
LandOfFree
Fused aryl substituted imidazole angiotensin II receptor inhibit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused aryl substituted imidazole angiotensin II receptor inhibit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused aryl substituted imidazole angiotensin II receptor inhibit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1351801